Anti Vegf Eylea 2mg denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) as Not FDA-Approved

A "not FDA-approved" denial means UHC's claim processing system or clinical reviewer concluded that either (a) the drug itself lacks FDA approval for the submitted indication, or (b) the diagnosis code on the claim does not correspond to any FDA-approved indication for Eylea 2 mg. This type of denial frequently results from a mismatch between the ICD-10 code submitted and the indication language in the FDA label, from an outdated UHC policy that has not yet been updated to reflect a newer approval, or from a coding error in the original submission.

## Why This Denial Is Appealable

If Eylea 2 mg has FDA approval for your condition — which you should verify against the current FDA-approved prescribing label on DailyMed — this denial is factually incorrect and must be overturned. The corrective path is straightforward: document the FDA approval, align the diagnosis code to the approved indication language, and present both in your appeal. Even if the original claim used an imprecise code, the appeal process allows you to correct the record with supporting clinical documentation.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline specified in your denial letter. Under ERISA §503 and ACA rules, UHC must provide a full and fair review that considers new clinical information you submit.
• External review (ACA §2719): If UHC upholds the denial, escalate to an IRO within approximately four months. "Not FDA-approved" denials grounded in a disputed clinical or factual determination are eligible for external review.
• Expedited option: Request the 72-hour expedited pathway if a delay in treatment poses a serious risk to your vision.

## Documentation to Gather

1. FDA label — print the complete current prescribing information for Eylea 2 mg from the FDA label repository or DailyMed. Highlight the exact indication that applies to your diagnosis. 2. Diagnosis-to-label alignment — a side-by-side comparison showing that the ICD-10 code submitted matches the indication language in the FDA label, prepared with input from your billing team or prescriber. 3. Chart documentation — ophthalmology notes, imaging reports, and diagnostic findings confirming the diagnosis that corresponds to the approved indication. 4. Prescriber letter — your retinal specialist should confirm the specific FDA-approved indication being treated and explicitly state that the use is not off-label. 5. UHC coverage policy — obtain UHC's current anti-VEGF medical policy to confirm whether any additional criteria beyond FDA approval are required and address them.

## Criteria-Mapping Structure

Your appeal letter should open with the single most important fact: the FDA approval status and date for the relevant indication. Then present the criteria map — UHC's policy requirements in the left column, chart or label evidence in the right. For this denial type, the map is usually brief because the central dispute is factual rather than clinical: either the drug is approved for the indication or it is not, and the label resolves the question.